GNPX Genprex Inc.: Accounting Value per Share

Public company logo of Genprex Inc. (GNPX)

The book value per share for Genprex, Inc. (GNPX) is clearly displayed on GURU.Markets, with the current level sitting around 29.25. Genprex, Inc. leads in oncology gene therapy through the development of ONCOPRX AI-nanoparticles. The company relies on external contractors for manufacturing and testing, maintaining its position as a scientific hub. A lack of revenue and the pending FDA verdict deprive the business of the ability to exercise pricing power.

Genprex Inc. (GNPX) - Accounting Value per Share from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for genprex.com (GNPX)

- price and consensus price forecast:
Price Chart Genprex, Inc|GNPX - Forecast Levels Chart
- market capitalization data:
Market Valuation Genprex, Inc.|GNPX - Business Value
- book capitalization data:
Book Value per Share Genprex|GNPX - Company Net Assets|Market Capitalization to Book Value Ratio genprex.com|GNPX - Company Total Assets
- debt and liquidity data:
Debt to Equity Genprex, Inc.|GNPX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Genprex|GNPX - Company Total Debt|Debts to Book Capitalization Genprex, Inc.
Analysis of all company metrics:Genprex, Inc, GNPX
Manufactured product of genprex.com

Geopolitical barriers and reagent supply disruptions are hindering the international research of Genprex, Inc. (GNPX), directly impacting the capitalization of its intangible assets. The current trend in book value per share reflects the equity portion per share, allowing investors to assess the business's intrinsic value without market noise and identify the risk of overpaying for the company's illiquid resources.

Competitor analysis for Genprex, Inc.

Net Assets per Single Share BeiGene Corp|Halozyme Corp (HALO) - Share Book Value|Accounting Value per Share Revolution Medicines|ascentage.com (AAPG) - Equity per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|RADX: Book Value per Share|Book Value of One Share artivabio.com (ARTV)|ANL: Book Value per Share|Veru Inc - Net Asset Value per Share|Tempest Tx (TPST) - Net Assets per Single Share|XLO: Equity per Share|Net Assets per Single Share renovarobio.com (RENB)|MURA (Mural Oncology) - Share Book Value|KAPA - Net Assets per Single Share|Accounting Value of a Share OnKure|CytoMed Therapeutics - Book Value per Share|Net Asset Value per Share curis.com CRIS|APLM - Accounting Value per Share|THAR - Equity per Share|Accounting Value per Share Advanced Biomed Corp (ADVB)|CLDI - Accounting Value of a Share|Sunshine Biopharma, Inc. - Book Value per Share|XBIO (Xenetic Biosciences, Inc.) - Net Assets per Share|Net Assets per Single Share Salarius Pharmaceuticals (SLRX)|Equity per Share purple-biotech.com|Book Value per Share AONC (American Oncology Network)|Accounting Value per Share BeiGene Ltd. BGNE|Accounting Value per Share CKPT|Net Assets per Share elevationoncology.com ELEV|Book Value per Share ICAD|IKNA: Book Value of One Share|Net Assets per Single Share Notable Labs|VIRX (Viracta Therapeutics, Inc.) - Equity per Share|Net Assets per Single Share MorphoSys Corp MOR|Share Book Value NAYA Biosciences Corp (NAYA)|Accounting Value per Share Ascentage Pharma Group AAPGV